Literature DB >> 9886578

Meloxicam inhibits the growth of colorectal cancer cells.

A P Goldman1, C S Williams, H Sheng, L W Lamps, V P Williams, M Pairet, J D Morrow, R N DuBois.   

Abstract

Cyclooxygenase-2 has been reported to play an important role in colorectal carcinogenesis. The effects of meloxicam (a COX-2 inhibitor) on the growth of two colon cancer cell lines that express COX-2 (HCA-7 and Moser-S) and a COX-2 negative cell line (HCT-116) were evaluated. The growth rate of these cells was measured following treatment with meloxicam. HCA-7 and Moser-S colony size were significantly reduced following treatment with meloxicam; however, there was no significant change in HCT-116 colony size with treatment. In vivo studies were performed to evaluate the effect of meloxicam on the growth of HCA-7 cells when xenografted into nude mice. We observed a 51% reduction in tumor size after 4 weeks of treatment. Analysis of COX-1 and COX-2 protein levels in HCA-7 tumor lysates revealed a slight decrease in COX-2 expression levels in tumors taken from mice treated with meloxicam and no detectable COX-1 expression. Here we report that meloxicam significantly inhibited HCA-7 colony and tumor growth but had no effect on the growth of the COX-2 negative HCT-116 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886578     DOI: 10.1093/carcin/19.12.2195

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  24 in total

1.  COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.

Authors:  B J Whittle
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

2.  Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.

Authors:  C S Williams; A P Goldman; H Sheng; J D Morrow; R N DuBois
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.

Authors:  Hui-Hua Chang; Zuohe Song; Lee Wisner; Tina Tripp; Vijay Gokhale; Emmanuelle J Meuillet
Journal:  Invest New Drugs       Date:  2011-09-20       Impact factor: 3.850

Review 4.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.

Authors:  Milind Rao; Wenxuan Yang; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

Review 5.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

6.  Meloxicam-loaded nanocapsules as an alternative to improve memory decline in an Alzheimer's disease model in mice: involvement of Na(+), K(+)-ATPase.

Authors:  Francine R Ianiski; Catiane B Alves; Carla F Ferreira; Virginia C Rech; Lucielli Savegnago; Ethel A Wilhelm; Cristiane Luchese
Journal:  Metab Brain Dis       Date:  2016-02-27       Impact factor: 3.584

7.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.

Authors:  C S Williams; H Sheng; J A Brockman; R Armandla; J Shao; M K Washington; A G Elkahloun; R N DuBois
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

8.  Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers.

Authors:  Bing Xin; Yoshihito Yokoyama; Tatsuhiko Shigeto; Hideki Mizunuma
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Authors:  Daniela Stoppoloni; Claudia Canino; Irene Cardillo; Alessandra Verdina; Alfonso Baldi; Ada Sacchi; Rossella Galati
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

Review 10.  Targeting the eicosanoid pathway in non-small-cell lung cancer.

Authors:  Leora Horn; Michael Backlund; David H Johnson
Journal:  Expert Opin Ther Targets       Date:  2009-05-02       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.